NLV-III will be managed by the New Leaf team, which currently manages NLV-I, NLV-IL, and

Il. THE TEAM NLV-III will be managed by the New Leaf team, which currently manages NLV-I, NLV-IL, and provides sub-advisory services managing the remaining healthcare technology investments in the Sprout Funds. The team of six senior partners, five of whom have worked together continuously for over a decade, stands out in the industry for its depth of accomplishments, track record of consistent investment success, and its organizational stability. Each of the senior partners has a strong combination of significant and relevant industry operating experience and venture capital investment experience from one or more of the Fund’s targeted sectors. The New Leaf team is further strengthened by a group of experienced investment professionals who add highly relevant scientific backgrounds and investment experience. The following timeline shows the history and progression of the New Leaf team: History and Progression of New Leaf Team Donaldson, Lufkin & Jenrette ("DLJ") Qedit Suisse Arst Boston ("CSFB") Independent (New Leaf Ventures) Sprout Growth IL || Sprout Capital VII Sprout Capital VIII} Sprout Capital IX New Leaf New Leaf $204 million $250 milion $750 milion $1.1 billion * Ventures I Ventures I HCT: 8% Cost HCT: 40% Cost HCT. 21% Cost HCT: 65% Cost $310 milion $450 million 1993 | 1995, 1997 | 1999 | 2001 | 2003 2005, 2007 2009 2011 2013 s @ 2 SENIOR TEAM Philippe Chambon, MD, Ph.D., (55), Managing Director, helped found New Leaf in 2005. Philippe joined Sprout in 1995 and since that time has been an active investor in all three sectors of interest for NLV-III. His investments have spanned all stages including six start ups and several later stage growth equity investments and one buy-out. Philippe is currently focused on New Leaf’s Information Convergence sector and late stage biopharmaceutical investments. Philippe is currently on the boards of directors of Treato, Truveris, Karos Pharmaceuticals, Principia BioPharma and VaxInnate. He was previously on the boards of NxStage Medical (NASDAQ: NXTM), Auxilium (NASDAQ: AUXL), ePocrates (NASDAQ: EPOC, acquired by athenahealth), Nuvelo (NASDAQ: NUVO), Sapient Health Network (acquired by WebMD), Spotfire (acquired by Tibco Software), and Combichem (acquired by DuPont). He also led our investment in, and was a board observer at, Audax Health (acquired by UnitedHealth/Optum). Immediately prior to joining Sprout, Philippe was a Manager in the healthcare practice of the Boston Consulting Group. In that capacity, he managed strategy and business re-engineering assignments with clients in the pharmaceutical, biotech and insurance industry. Previously, Philippe was an executive with Sandoz Pharmaceutical for seven years, where he built and led an organization responsible for late stage clinical project management, portfolio management, and pre-marketing and pharmacoeconomics activities. He conducted graduate research in 11 CONTROL NUMBER 257 - CONFIDENTIAL HOUSE_OVERSIGHT_024022